API Tucatinib

Tucatinib More Info

Tucatinib (brand name Tukysa) is an oral, small-molecule tyrosine-kinase inhibitor that is highly selective for the HER2 (human epidermal growth-factor receptor 2) tyrosine-kinase domain. It was developed to bind reversibly to the intracellular ATP-binding site of HER2, thereby blocking downstream PI3K/AKT and MAPK signaling pathways that drive tumor-cell proliferation and survival.

Key points:

Mechanism of action

High selectivity for HER2 minimizes off-target inhibition of EGFR, translating into a lower incidence of EGFR-related toxicities such as skin rash and diarrhea.

Penetrates the blood–brain barrier, providing activity against HER2-positive brain metastases.

Approved indications (U.S. FDA)

Metastatic HER2-positive breast cancer: used in combination with trastuzumab and capecitabine for adults who have received one or more prior anti-HER2 regimens.

RAS wild-type HER2-positive unresectable or metastatic colorectal cancer: used with trastuzumab after progression on fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy (accelerated approval).

Clinical efficacy highlights

In the pivotal HER2CLIMB trial, adding tucatinib to trastuzumab + capecitabine reduced the risk of disease progression or death by 46% (HR 0.54) and the risk of death by 34% (HR 0.66) versus placebo-combination; 1-year PFS in patients with brain metastases was 24.9% vs 0%, respectively.

Dosing and administration

Recommended dose: 300 mg orally twice daily (with or without food) until disease progression or unacceptable toxicity.

Tablets are swallowed whole; dose modifications are guided by hepatic function and adverse-event severity.

Safety profile

Common adverse events: diarrhea, palmar-plantar erythrodysesthesia, nausea, vomiting, fatigue, and increased aminotransferases.

Grade ≥3 toxicities (e.g., diarrhea, elevated liver enzymes) occur more frequently than with placebo but are generally manageable with dose adjustments and supportive care.

Pharmacoeconomic considerations

Cost-effectiveness analyses indicate that while tucatinib adds substantial survival benefit, its high acquisition cost challenges health-technology-assessment bodies; price-reduction negotiations are ongoing in several jurisdictions.

In summary, tucatinib is a potent, brain-penetrant HER2-directed tyrosine-kinase inhibitor that extends progression-free and overall survival in heavily pretreated HER2-positive metastatic breast cancer and shows promising activity in HER2-positive colorectal cancer.